Yet, many hitches like mutations, incomplete epigenetic reprogramming and tumors formation, which accompany the use of iPSCs, should be solved as well. Therefore, further understanding of iPSCs, including a genome-wide epigenetic characterization of those cells and further studying of their genomic stability, is needed before beginning their clinical applications in the area of regenerative medicine for treating human diseases, mainly the intractable ones (Table 5). Indeed, these patient-specific hiPSCs will serve in the future as precursors for transplantation and tissue regeneration therapy, as well as a copious resource for in vitro and in vivo disease modeling and drug and genetic screening (Figure 2).
